Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding, First-in-Human Study to Describe the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults

Trial Profile

A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding, First-in-Human Study to Describe the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Respiratory syncytial virus vaccine (Primary) ; Influenza virus vaccine
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Jun 2018 Planned End Date changed from 4 Dec 2019 to 30 Oct 2019.
    • 14 Jun 2018 Planned primary completion date changed from 4 Dec 2019 to 30 Oct 2019.
    • 23 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top